Registration prerequisites in China and South Korea MCQs With Answer

Introduction:

Registration prerequisites in China and South Korea MCQs With Answer

This quiz set is designed for M.Pharm students studying Regulatory Aspects of Drugs & Cosmetics. It focuses on practical prerequisites and regulatory expectations for drug registration in China and South Korea, comparing dossier requirements, local representation, clinical data acceptance, GMP and stability documentation, samples and labeling, pharmacovigilance obligations, and accelerated approval pathways. The questions probe deeper into dossier structure (CTD/eCTD), manufacturing and quality evidence, bioequivalence and clinical bridging, and administrative steps required before marketing authorisations. Use these MCQs to test your readiness for regulatory submissions and to reinforce country-specific regulatory strategies for product registration in these two major Asian markets.

Q1. Which regulatory authority is primarily responsible for drug registration and approval in China?

• Ministry of Health (MOH)
• China Food and Drug Administration (CFDA)
• National Medical Products Administration (NMPA)
• State Drug Control Bureau (SDCB)

Correct Answer: National Medical Products Administration (NMPA)

Q2. In South Korea, which agency oversees medicinal product approvals and regulatory control?

• Korean Drug Safety Agency (KDSA)
• Ministry of Health and Welfare (MOHW)
• Ministry of Food and Drug Safety (MFDS)
• Korean Pharmaceutical Regulatory Authority (KPRA)

Correct Answer: Ministry of Food and Drug Safety (MFDS)

Q3. Which dossier format is accepted and commonly required by both China (NMPA) and South Korea (MFDS) for new drug registrations?

• Bill of Materials (BOM) format
• Common Technical Document (CTD) / electronic CTD (eCTD)
• US NDA-only format
• Paper-only dossier without CTD structure

Correct Answer: Common Technical Document (CTD) / electronic CTD (eCTD)

Q4. For foreign applicants, what is typically required by both NMPA and MFDS regarding representation in-country?

• No representation is allowed; foreign firms must submit directly
• Appointment of a local authorised representative or legal agent
• Only an in-country manufacturing site is required, not a representative
• Registration through a third-party distributor is mandatory

Correct Answer: Appointment of a local authorised representative or legal agent

Q5. Which of the following is a common GMP-related prerequisite for drug registration in China and South Korea?

• Local GMP certification issued by a third-party private company
• Manufacturing site must hold GMP compliance evidence, often inspection report or certificate
• Only a quality agreement is required; GMP certificates are optional
• GMP is not applicable if the manufacturing site is outside the country

Correct Answer: Manufacturing site must hold GMP compliance evidence, often inspection report or certificate

Q6. How do NMPA and MFDS generally treat foreign clinical trial data submitted in support of marketing authorization?

• They always reject foreign data and require full local trials
• They may accept foreign clinical data if it is scientifically justified and relevant to local population
• They accept foreign data only from US trials
• They accept foreign data without any review or justification

Correct Answer: They may accept foreign clinical data if it is scientifically justified and relevant to local population

Q7. Which type of additional clinical requirement is commonly requested for generics seeking approval in China?

• Full Phase III global clinical program
• Quality and Efficacy Consistency Evaluation or bioequivalence studies
• No clinical or BE data is needed for generics
• Pediatric-only clinical trials

Correct Answer: Quality and Efficacy Consistency Evaluation or bioequivalence studies

Q8. For stability data submission, which of the following is a usual prerequisite for dossiers submitted to NMPA and MFDS?

• No stability data is required at submission
• Long-term and accelerated stability data according to ICH or local guidelines
• Only in-use stability for finished product is required
• Stability data from any packaging is acceptable without protocol

Correct Answer: Long-term and accelerated stability data according to ICH or local guidelines

Q9. Which language requirement is typically enforced for labeling and patient information when registering a drug in China and South Korea?

• English labeling only is acceptable
• Labeling and leaflet must be provided in the local official language (Chinese/Korean)
• Any UN language is acceptable
• Latin is preferred for all regulatory labels

Correct Answer: Labeling and leaflet must be provided in the local official language (Chinese/Korean)

Q10. What regulatory document serves as proof of marketing authorization after approval in China?

• Drug Export Permit
• Certificate of Pharmaceutical Import-Export
• Drug Registration Certificate (or Marketing Authorization)
• Production Batch Release Certificate

Correct Answer: Drug Registration Certificate (or Marketing Authorization)

Q11. Which of the following is a common administrative prerequisite before starting clinical trials (CTA/IND) in China and South Korea?

• Submission of final marketing authorization application only
• Approval of Clinical Trial Application (CTA) or IND from NMPA/MFDS and local ethics committee approval
• Only a sponsor’s internal review is required
• GMP certificate for the clinical site

Correct Answer: Approval of Clinical Trial Application (CTA) or IND from NMPA/MFDS and local ethics committee approval

Q12. What is typically required by both regulators regarding pharmacovigilance for approved products?

• No pharmacovigilance system is required for foreign companies
• A functional pharmacovigilance system and a qualified local contact person for safety reporting
• Only an annual safety statement without routine reporting
• Pharmacovigilance can be outsourced without any local contact

Correct Answer: A functional pharmacovigilance system and a qualified local contact person for safety reporting

Q13. For novel drug applications, which expedited pathway is available in either China or South Korea to shorten review timelines?

• Conditional approval, priority review, or breakthrough designation mechanisms
• Only standard review with fixed timelines, no expedited options
• Emergency use without any data submission
• Automatic approval upon dossier submission

Correct Answer: Conditional approval, priority review, or breakthrough designation mechanisms

Q14. Which element of CMC (Chemistry, Manufacturing and Controls) is commonly scrutinised by both NMPA and MFDS?

• Only the country of origin of raw materials
• Comprehensive CMC including drug substance characterization, manufacturing process, specifications, and batch analyses
• Only final product container type
• Marketing claims and promotional strategy

Correct Answer: Comprehensive CMC including drug substance characterization, manufacturing process, specifications, and batch analyses

Q15. When submitting samples for laboratory testing during registration, what is typically expected by the regulators?

• Samples are not required if a certificate is provided
• Submission of representative finished product batches and drug substance samples for independent testing
• Only photographs of the product are required
• Samples must be supplied in non-sterile packaging only

Correct Answer: Submission of representative finished product batches and drug substance samples for independent testing

Q16. Which of the following best describes acceptance of GMP certificates by NMPA and MFDS from recognized foreign authorities?

• They automatically accept any certificate without review
• They may accept GMP certificates from recognized authorities but still reserve the right to inspect or request additional evidence
• They never accept foreign GMP certificates
• They only accept certificates issued within the last month

Correct Answer: They may accept GMP certificates from recognized authorities but still reserve the right to inspect or request additional evidence

Q17. For biologics and advanced therapies, which additional regulatory prerequisite is likely compared to small molecules?

• No additional requirements beyond small molecule dossiers
• More detailed characterisation, comparability data, and facility-specific information including cell banking and viral safety
• Only marketing price negotiations
• Only a simplified dossier due to complexity

Correct Answer: More detailed characterisation, comparability data, and facility-specific information including cell banking and viral safety

Q18. Regarding fees and timelines, which statement is generally correct for submissions to NMPA and MFDS?

• There are no fees and reviews are always completed within 30 days
• Submission fees apply and review timelines vary depending on product type and whether priority pathways are used
• Fees are refundable in full if application is rejected
• Fees are fixed globally and do not vary by application complexity

Correct Answer: Submission fees apply and review timelines vary depending on product type and whether priority pathways are used

Q19. What documentation is commonly required to demonstrate the drug master file (DMF) or active substance control strategy?

• Only a simple certification letter from the supplier
• Detailed drug substance DMF or equivalent information including manufacturing, controls, specifications, and stability
• No DMF is allowed in China or Korea
• Only analytic method descriptions without validation data

Correct Answer: Detailed drug substance DMF or equivalent information including manufacturing, controls, specifications, and stability

Q20. Which post-approval obligation is commonly required by both regulatory agencies after a product is marketed?

• There are no post-approval obligations once a product is approved
• Post-marketing surveillance, periodic safety update reports (PSURs) or equivalent pharmacovigilance reporting
• Mandatory transfer of marketing rights to a local company immediately
• Quarterly public promotion reports to government

Correct Answer: Post-marketing surveillance, periodic safety update reports (PSURs) or equivalent pharmacovigilance reporting

Download